A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Clinical trial NCT06384547 · COMPLETED

Trial details

NCT number: NCT06384547
Sponsor: Viridian Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Thyroid Eye Disease

Start date: 2024-05-23
Primary completion: 2025-05-01
Enrollment: 231

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.